Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Paradoxical vasoconstrictive effects of H2S on shear stress‐mediated vasodilation
Lee, Hon‐Chi, Chai, Qiang , Chai, Qiang, Lü, Tong , Wang, Xiao‐Li

Mayo Clinic

The FASEB Journal | June 16, 2021 | Volume: 27 | Issue: S1 | Pages: No page available

10.1096/fasebj.27.1_supplement.1185.2 Get It

We examined the role of H 2 S on shear stress‐mediated dilation of isolated mouse coronary arteries. Na 2 S produced concentration‐dependent dilation in these vessels, which was significantly inhibited by iberiotoxin. BK currents in mouse coronary smooth muscle cells were directly activated by Na 2 S, suggesting H 2 S produced vasodilation through BK channel activation. Using a pressure servo controller system, freshly isolated mouse coronary arteries were subjected to physiological levels of shear stress (1 to 25 dynes/cm 2 ), producing graded dilatory responses, but such effects were diminished in the presence of 100 μM Na 2 S. Pre‐incubation with the cystathionine γ‐lyase inhibitor, D,L‐propargylglycine (PPG), resulted in a paradoxical augmentation of shear stress‐mediated vasodilation. However, in the presence of L‐NAME or in coronary arteries from eNOS knockout mice, PPG inhibited shear stress‐mediated vasodilation, suggesting an interaction between NO and H 2 S signaling. Using cultured bovine aortic endothelial cells, eNOS activity was inhibited by Na 2 S. These results suggest that both NO and H 2 S are important shear stress‐mediated vasodilators in mouse coronary arteries but there is a complex interaction between these two signaling pathways that results in paradoxical vasoconstrictive effects of H 2 S through inhibition of NO generation. (Supported by grants from NIH)
Drug‐induced constipation alters gut microbiota stability leading to physiological changes in the host (1118.2)
Touw, Ketrija, Wang, Yunwei , Leone, Vanessa , Nadimpalli, Anuradha, Nathaniel, Hubert, Farrugia, Gianrico, Kashyap, Purna , Chang, Eugene B. , Farrugia, Gianrico

Mayo Clinic

The FASEB Journal | June 16, 2021 | Volume: 28 | Issue: S1 | Pages: No page available

10.1096/fasebj.28.1_supplement.1118.2 Get It

Gut microbes play a significant role in development and maintenance of intestinal functions, but can contribute to pathogenesis of gastrointestinal (GI) disorders when host‐microbiome relationship is perturbed. In this study we sought to examine how constipation affects microbiome, and how these alterations in turn affect the host. Adult C57Bl/6 mice were treated with 0.1% Loperamide in drinking water for 7 days to induce constipation. Loperamide‐treated mice had increased GI transit time, indicating constipation. Bacterial DNA analysis by HiSeq sequencing showed decreased Firmicutes and increased Bacteroidetes in constipated mice. Microbiome metabolic potential was measured with tetrazolium dye assay and showed shift toward increased sugar metabolism in Loperamide‐treated mice. Microbial metabolites were measured by GC‐MS, and showed lower butyrate concentration in constipated mice. To determine constipation effects on the host, we introduced microbiota from constipated donors to germ‐free recipients. These mice had delayed GI transit time. To determine mechanism for delayed GI transit we analyzed colon tissues by qRT‐PCR and western blotting analysis, and determined lower expression of nNos mRNA and protein levels in these mice. Overall, these results suggest that delayed GI transit shifts microbiome taxonomic and metabolic profile, and these changes further contribute to development of constipation. Grant Funding Source : NIH NIDDK T32 DK07074
Comparative Cost Effectiveness of Reflux-Based and Reflux-Independent Strategies for Barrett's Esophagus Screening
Sami, Sarmed S. , Rosedahl, Jordan K., Katzka, David A. , Wang, Kenneth K, Ragunath, Krish , Rubenstein, Joel H. , Iyer, Prasad G. , Moriarty, James P. , Borah, Bijan J. , Kisiel, John B.

Mayo Clinic

American Journal of Gastroenterology | June 16, 2021 | Volume: 116 | Issue: 8 | Pages: 1620-1631

10.14309/ajg.0000000000001336 | PMID 34131096 Get It

INTRODUCTION: Minimally invasive tests for Barrett's esophagus (BE) detection have raised the prospect of broader nonreflux-based testing. Cost-effectiveness studies have largely studied men aged 50 years with chronic gastroesophageal reflux disease (GERD) symptoms. We evaluated the comparative cost effectiveness of BE screening tests in GERD-based and GERD-independent testing scenarios. METHODS: Markov modeling was performed in 3 scenarios in 50 years old individuals: (i) White men with chronic GERD (GERD-based); (ii) GERD-independent (all races, men and women), BE prevalence 1.6%; and (iii) GERD-independent, BE prevalence 5%. The simulation compared multiple screening strategies with no screening: sedated endoscopy (sEGD), transnasal endoscopy, swallowable esophageal cell collection devices with biomarkers, and exhaled volatile organic compounds. A hypothetical cohort of 500,000 individuals followed for 40 years using a willingness to pay threshold of $100,000 per quality-adjusted life year (QALY) was simulated. Incremental cost-effectiveness ratios (ICERs) comparing each strategy with no screening and comparing screening strategies with each other were calculated. RESULTS: In both GERD-independent scenarios, most non-sEGD BE screening tests were cost effective. Swallowable esophageal cell collection devices with biomarkers were cost effective (<$35,000/QALY) and were the optimal screening tests in all scenarios. Exhaled volatile organic compounds had the highest ICERs in all scenarios. ICERs were low (<$25,000/QALY) for all tests in the GERD-based scenario, and all non-sEGD tests dominated no screening. ICERs were sensitive to BE prevalence and test costs. DISCUSSION: Minimally invasive nonendoscopic tests may make GERD-independent BE screening cost effective. Participation rates for these strategies need to be studied.
Neurological Complications of Cardiac Procedures
Hrdlicka, Courtney M. , Wang, Jeffrey , Selim, Magdy H.

Mayo Clinic

Seminars in Neurology | June 15, 2021 | Volume: 41 | Issue: 04 | Pages: 398-410

10.1055/s-0041-1728761 | PMID 34130332 Get It

AbstractNeurological complications after cardiac surgery and percutaneous cardiac interventions are not uncommon. These include periprocedural stroke, postoperative cognitive dysfunction after cardiac surgery, contrast-induced encephalopathy after percutaneous interventions, and seizures. In this article, we review the incidence, pathophysiology, diagnosis, and management of these complications. Improved understanding of these complications could lead to their prevention, faster detection, and facilitation of diagnostic workup and appropriate treatment.
Early role for a Na + ,K + -ATPase ( ATP1A3 ) in brain development
Smith, Richard S. , Akula, Shyam K. , Neil, Jennifer E., Wang, Yidi , Hill, Robert , Goldman, Melissa , Mullally, Christopher D. , Reed, Nora , Bello‐Espinosa, Luis , Flores‐Sarnat, Laura , Monteiro, Fabíola Paoli , Casella, Erasmo Barbante , Barkovich, A. James , Gonzalez–Heydrich, Joseph , Florio, Marta , Akula, Shyam K , Wang, Yidi , Bello-Espinosa, Luis , Erasmo, Casella B , Vairo, Filippo , Barkovich, A James , Gonzalez-Heydrich, Joseph , Walsh, Christopher A , Hill, R. Sean, Vairo, Filippo Pinto e , Morava, Éva , Brownstein, Catherine A. , McCarroll, Steven A. , Walsh, Christopher A.

Mayo Clinic

Proceedings of the National Academy of Sciences | June 14, 2021 | Volume: 118 | Issue: 25 | Pages: No page available

10.1073/pnas.2023333118 | PMID 34161264 Get It

Significance By evaluating children with a malformed cerebral cortex, we identified an ATPase pump (ATP1A3) with an early role in brain development. The ATP1A3 pump maintains the physiological concentration of sodium and potassium ions in cells, a process critical for osmotic equilibrium and membrane potential across several developing cell populations. We employed single-cell sequencing approaches to identify key enrichments for ATP1A3 expression during human cortex development. Unravelling this early cell-type–specific pathophysiology in the developing brain offers a potential basis for the treatment of ATP1A3 -related diseases affecting prenatal and early childhood development.
Microglia show differential transcriptomic response to Aβ peptide aggregates ex vivo and in vivo
McFarland, Karen N. , Ceballos, Carolina, Rosario, Awilda M., Ladd, Thomas B., Golde, Todd E. , Wang, Xue , Allen, Mariet , Ertekin‐Taner, Nilüfer , Funk, Cory C. , Robinson, Max , Rappaport, Noa , Chakrabarty, Paramita , Golde, Todd E , Rappaport, Noa , Ceballos, Carolina, Moore, Brenda D. , Baloni, Priyanka

Mayo Clinic

Life Science Alliance | June 14, 2021 | Volume: 4 | Issue: 7 | Pages: e202101108

10.26508/lsa.202101108 | PMID 34127518 Get It

Aggregation and accumulation of amyloid-β (Aβ) is a defining feature of Alzheimer’s disease pathology. To study microglial responses to Aβ, we applied exogenous Aβ peptide, in either oligomeric or fibrillar conformation, to primary mouse microglial cultures and evaluated system-level transcriptional changes and then compared these with transcriptomic changes in the brains of CRND8 APP mice. We find that primary microglial cultures have rapid and massive transcriptional change in response to Aβ. Transcriptomic responses to oligomeric or fibrillar Aβ in primary microglia, although partially overlapping, are distinct and are not recapitulated in vivo where Aβ progressively accumulates. Furthermore, although classic immune mediators show massive transcriptional changes in the primary microglial cultures, these changes are not observed in the mouse model. Together, these data extend previous studies which demonstrate that microglia responses ex vivo are poor proxies for in vivo responses. Finally, these data demonstrate the potential utility of using microglia as biosensors of different aggregate conformation, as the transcriptional responses to oligomeric and fibrillar Aβ can be distinguished.
Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient Screening
Requena, David , Ramos‐Espiritu, Lavoisier , Ng, Denise , Bhola, Patrick , Jong, Ype P. de , Wang, Ruisi , Narayan, Nicole J.C., Shebl, Bassem , Michailidis, Eleftherios , Vercauteren, Koen , Hurley, Arlene , Farber, Benjamin A. , Hammond, William J. , Saltsman, James A. , Weinberg, Ethan M. , Glickman, J. Fraser , Lyons, Barbara A. , Ellison, Jessica, Schadde, Erik , Hertl, Martin, Leiting, Jennifer L. , Truty, Mark J. , Smoot, Rory L. , Tierney, Faith, Kato, Tomoaki , Wendel, Hans‐Guido , Rice, Charles M. , Letai, Anthony , Simon, Sanford M. , Requena, David , de Jong, Ype P , Michailidis, Eleftherios , Vercauteren, Koen O A , Hurley, Arlene M , Farber, Benjamin A , Hammond, William J , Glickman, J Fraser , Leiting, Jennifer L , Smoot, Rory L , LaQuaglia, Michael P , Simon, Sanford M , Weinberg, Ethan M , Lalazar, Gadi , Levin, Solomon , Kabbani, Mohammad , LaQuaglia, Michael P. , Coffino, Philip , Torbenson, Michael , Ortiz, Michael V.

Mayo Clinic

Cancer Discovery | June 14, 2021 | Volume: 11 | Issue: 10 | Pages: 2544-2563

10.1158/2159-8290.cd-20-0872 | PMID 34127480 Get It

Abstract To repurpose therapeutics for fibrolamellar carcinoma (FLC), we developed and validated patient-derived xenografts (PDX) from surgical resections. Most agents used clinically and inhibitors of oncogenes overexpressed in FLC showed little efficacy on PDX. A high-throughput functional drug screen found primary and metastatic FLC were vulnerable to clinically available inhibitors of TOPO1 and HDAC and to napabucasin. Napabucasin's efficacy was mediated through reactive oxygen species and inhibition of translation initiation, and specific inhibition of eIF4A was effective. The sensitivity of each PDX line inversely correlated with expression of the antiapoptotic protein Bcl-xL, and inhibition of Bcl-xL synergized with other drugs. Screening directly on cells dissociated from patient resections validated these results. This demonstrates that a direct functional screen on patient tumors provides therapeutically informative data within a clinically useful time frame. Identifying these novel therapeutic targets and combination therapies is an urgent need, as effective therapeutics for FLC are currently unavailable. Significance: Therapeutics informed by genomics have not yielded effective therapies for FLC. A functional screen identified TOPO1, HDAC inhibitors, and napabucasin as efficacious and synergistic with inhibition of Bcl-xL. Validation on cells dissociated directly from patient tumors demonstrates the ability for functional precision medicine in a solid tumor. This article is highlighted in the In This Issue feature, p. 2355
Association Between Smoking and Molecular Subtypes of Colorectal Cancer
Wang, Xiaoliang , Amitay, Efrat L. , Harrison, Tabitha A. , Banbury, Barbara L. , Berndt, Sonja I. , Brenner, Hermann , Buchanan, Daniel D. , Campbell, Peter T. , Cao, Yin , Chang‐Claude, Jenny , Gallinger, Steven , Giannakis, Marios , Gunter, Marc J. , Nishihara, Reiko , Phipps, Amanda I. , Slattery, Martha L. , Song, Mingyang , Thibodeau, Steven, Guelpen, Bethany Van , Woods, Michael O. , Hoffmeister, Michael , Peters, Ulrike , Amitay, Efrat L , Chang-Claude, Jenny , Gunter, Marc J , Jenkins, Mark A , Moreno, Victor , Ogino, Shuji , Sakoda, Lori C , Schoen, Robert E , Song, Mingyang , Sun, Wei , Thibodeau, Steven N, Toland, Amanda Ewart , Woods, Michael O , Hoffmeister, Michael , Buchanan, Daniel D , Campbell, Peter T , Cao, Yin , Harrison, Tabitha A , Van Guelpen, Bethany , Brenner, Hermann , Wang, Xiaoliang , Chan, Andrew T. , Giles, Graham G. , Hopper, John L. , Jenkins, Mark A. , Lin, Yi , Moreno, Vı́ctor , Newcomb, Polly A. , Sakoda, Lori C. , Schoen, Robert E. , Sun, Wei , Hsu, Li

Mayo Clinic

JNCI Cancer Spectrum | June 13, 2021 | Volume: 5 | Issue: 4 | Pages: No page available

10.1093/jncics/pkab056 | PMID 34377935 Get It

Abstract Background Smoking is associated with colorectal cancer (CRC) risk. Previous studies suggested this association may be restricted to certain molecular subtypes of CRC, but large-scale comprehensive analysis is lacking. Methods A total of 9789 CRC cases and 11 231 controls of European ancestry from 11 observational studies were included. We harmonized smoking variables across studies and derived sex study–specific quartiles of pack-years of smoking for analysis. Four somatic colorectal tumor markers were assessed individually and in combination, including BRAF mutation, KRAS mutation, CpG island methylator phenotype (CIMP), and microsatellite instability (MSI) status. A multinomial logistic regression analysis was used to assess the association between smoking and risk of CRC subtypes by molecular characteristics, adjusting for age, sex, and study. All statistical tests were 2-sided and adjusted for Bonferroni correction. Results Heavier smoking was associated with higher risk of CRC overall and stratified by individual markers (Ptrend &lt; .001). The associations differed statistically significantly between all molecular subtypes, which was the most statistically significant for CIMP and BRAF. Compared with never-smokers, smokers in the fourth quartile of pack-years had a 90% higher risk of CIMP-positive CRC (odds ratio = 1.90, 95% confidence interval = 1.60 to 2.26) but only 35% higher risk for CIMP-negative CRC (odds ratio = 1.35, 95% confidence interval = 1.22 to 1.49; Pdifference = 2.1 x 10-6). The association was also stronger in tumors that were CIMP positive, MSI high, or KRAS wild type when combined (Pdifference &lt; .001). Conclusion Smoking was associated with differential risk of CRC subtypes defined by molecular characteristics. Heavier smokers had particularly higher risk of CRC subtypes that were CIMP positive and MSI high in combination, suggesting that smoking may be involved in the development of colorectal tumors via the serrated pathway.